Last updated: May 9, 2026
What did SHIRE LLC sue CorePharma over in 2:14-cv-05694, and what does the case outcome mean for patent strategy?
What is the case and how did the dispute frame the IP issues?
Case: Shire LLC v. CorePharma, LLC
Court: U.S. District Court (case number 2:14-cv-05694)
Parties: Shire LLC (plaintiff) vs CorePharma, LLC (defendant)
A complete litigation summary with claim-level analysis requires docket entries and court filings that identify:
- asserted patent(s) (publication and patent numbers),
- the drug and formulation at issue,
- the filing mechanism (e.g., ANDA paragraph IV, 505(b)(2)),
- the asserted counts (infringement, declaratory judgment, induced/contributory theories),
- the procedural posture (motions to dismiss, claim construction, summary judgment, trial),
- the final disposition and whether any patents were invalidated or narrowed.
No such case-specific facts are present in the prompt provided, so a complete, accurate litigation summary cannot be produced from the information available.
What patents and drug product are at issue?
No patent numbers, drug name(s), dosage forms, or regulatory filing details are included in the provided prompt.
What procedural milestones shaped the outcome?
No docket timeline, ruling dates, or event types (e.g., TRO, PI, Markman, summary judgment, settlement) are included in the provided prompt.
What did the court decide?
No final judgment, dismissal order, settlement notice, or opinion text is included in the provided prompt.
Litigation analysis suitable for patent and R&D planning
How should IP teams read the likely strategic logic behind these suits?
Without the asserted patent(s), the specific product, and the court’s holdings, any attempt to map the dispute to infringement pathways (literal vs doctrine of equivalents), validity defenses (102/103, 112, obviousness-type double patenting), or design-around constraints (formulation, particle size, crystalline form, salt selection, dosing regimen) would be speculative.
To support business decisions, the analysis must be grounded in:
- the asserted claim scope,
- the court’s claim construction (if any),
- the infringement analysis method used (comparative testing, sameness of process parameters, structural/functional equivalence),
- the validity rationale and which statutory grounds succeeded or failed.
No such information is available in the prompt.
What are the business implications (only at a structural level)?
Even without case facts, patent-litigation outcomes typically drive three levers:
- Entry timing: whether the court enjoined product launch or delayed FDA approval.
- Claim scope clarity: whether claim construction narrows design-around options.
- Validity precedent: whether the decision strengthens or weakens the asserted estate.
However, applying those levers to this specific case requires the actual rulings and asserted patents.
What deliverables can be produced from the record?
A Shire LLC v. CorePharma litigation deliverable normally includes:
- Asserted IP table: patent number, expiry, key claim(s), priority date, prosecution history flags.
- ANDA/entry context: filing date, paragraphs challenged, listed patents, 30-month stay timeline.
- Infringement map: element-by-element comparison to accused product specifications.
- Validity map: invalidity grounds and the specific teachings/rationales relied on.
- Disposition: final outcome, injunction status, judgment on claims, and any appeal.
These items cannot be completed accurately without docket and filing content.
Key Takeaways
- The provided input contains only the case caption and case number (2:14-cv-05694) and does not include the factual record required for a litigation summary and patent analysis.
- A complete, accurate report must identify asserted patents, accused drug details, procedural milestones, and the final disposition. None of those elements are included here.
- No business-grade conclusions on infringement strength, validity risk, or design-around strategy can be made based solely on the prompt.
FAQs
What information is missing to summarize the litigation accurately?
The prompt does not include asserted patent numbers, drug product details, or docket outcomes.
Can I determine which patents were asserted from the case number alone?
Not from the information provided in the prompt.
Does this case likely involve an ANDA paragraph IV dispute?
The prompt does not state the regulatory posture, so the mechanism cannot be confirmed.
What does a successful Shire enforcement generally mean for generic entry?
Typically it can delay entry through injunctions and judgment-based barriers, but the specific effect here depends on the court’s actual disposition.
Can a patent strategy recommendation be made without claim construction or holdings?
No claim-level or holding-level analysis can be grounded without the court’s rulings and asserted claims.
References (APA)
- Shire LLC v. CorePharma, LLC, No. 2:14-cv-05694 (D. Ct.).
